Physician profile
Vasant Thacker
NPI 1679611461
$5,078.57
in general payments reported to CMS, 2019-2025
33 companies · $909 in 2025
The $909 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,463 · 2020: $690 · 2021: $564 · 2022: $530 · 2023: $435 · 2024: $488 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,831.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $825.86 | 2019-2021 | |
| Abbvie INC. | $723.06 | 2019-2025 | |
| Therapeuticsmd, INC. | $500.43 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $403.17 | 2024-2025 | Voquezna |
| Amgen INC. | $262.05 | 2023 | Evenity, Prolia |
| Madrigal Pharmaceuticals | $260.58 | 2025 | Rezdiffra |
| Lupin INC. | $236.42 | 2019-2020 | |
| Astellas Pharma US INC | $215.70 | 2020-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceuticals, INC. | $196.51 | 2021 | |
| Exeltis, USA INC. | $185.46 | 2023-2025 | Slynd |
| Myovant Sciences INC. | $166.99 | 2022 | |
| Avion Pharmaceuticals | $164.19 | 2019-2021 | |
| Emd Serono, INC. | $132.91 | 2024 | |
| Phadia US INC. | $104.84 | 2019 | |
| Coopersurgical, INC. | $87.09 | 2019-2025 | Paragard T 380a, Paragard T 380a |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $76.29 | 2025 | Gemtesa, Myfembree |
| Biohaven Pharmaceutical Holding Company Ltd. | $69.34 | 2022 | |
| Aspira Women'S Health INC | $66.16 | 2022 | |
| Becton, Dickinson and Company | $43.44 | 2024-2025 | Bd Onclarity |
| Dexcom, INC. | $40.52 | 2024 | Dexcom G6 Transmitter |
| Amag Pharmaceuticals, INC. | $36.60 | 2019-2020 | |
| Novo Nordisk INC | $36.04 | 2023 | Wegovy, Saxenda, Ozempic |
| Bausch Health US, LLC | $29.31 | 2021-2022 | |
| Biogen, INC. | $26.98 | 2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $26.98 | 2025 | |
| Exact Sciences Corporation | $25.91 | 2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $25.83 | 2019 | |
| Shield Therapeutics INC | $23.54 | 2024 | |
| Roche Diagnostics Corporation | $20.00 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $19.93 | 2025 | |
| Evofem Biosciences, INC. | $17.50 | 2021 | |
| Merck Sharp & Dohme LLC | $17.22 | 2019 | |
| Medicem INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasant Thacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.